Risk factors for acute liver enzyme abnormalities in HIV-hepatitis B virus-coinfected patients on antiretroviral therapy

Antiviral Therapy

Volumn 12, Issue 7, 2007, Pages 1115-1126

  Chauvel, Olivia ^a,b,c   Lacombe, Karine ^a,b,c   Bonnard, Philippe ^d   Lascoux Combe, Caroline ^e   Molina, Jean Michel ^e   Miailhes, Patrick ^f   Girard, Pierre Marie ^a   Carrat, Fabrice ^b  

^a HÔPITAL SAINT ANTOINE   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c INSERM   (France)

^d HÔPITAL TENON   (France)

^e SAINT LOUIS HOSPITAL   (France)

^f HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ATAZANAVIR; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; LOPINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CHOLESTASIS; CLINICAL TRIAL; COHORT ANALYSIS; CYTOLYSIS; DISEASE DURATION; FOLLOW UP; HEPATITIS B; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; PROSPECTIVE STUDY; RISK FACTOR; SIDE EFFECT; TREATMENT DURATION; VIRUS REPLICATION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHOLESTASIS; FEMALE; HEPATITIS B; HIV; HIV INFECTIONS; HUMANS; LIVER; LIVER DISEASES; MALE; MIDDLE AGED; RISK FACTORS; VIRAL LOAD;

EID: 36148970031     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Powderly WG. Long-term exposure to lifelong therapies. J Acquir Immune Defic Syndr 2002; 29:S28-S40.
2. Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA 2004; 292:251-265.
3. Puoti M, Spinetti A, Ghezzi A, et al. Mortality for liver disease in patients with HIV infection: a cohort study. J Acquir Immune Defic Syndr 2000; 24:211-217.
4. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32:492-497.
5. Salmon-Ceron D, Lewden C, Morlat P, et al. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol 2005; 42:799-805.
6. Konopnicki D, Mocroft A, de Wit S, et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005; 19:593-601.
7. Larsen C, Pialoux G, Salmon D, et al. Prévalence des coinfections par les virus des hépatites B et C dans la population VIH+, France, juin 2004 [Prevalence of hepatitis B and C coinfection in HIV-infected patients, France, June 2004]. BEH 2005:109-112. French.
8. Thio CL, Seaberg EC, Skolasky R Jr, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360:1921-1926.
9. Perrillo RP. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001; 120:1009-1022.
10. Pol S, Lebray P, Vallet-Pichard A. HIV infection and hepatic enzyme abnormalities: intricacies of the pathogenic mechanisms. Clin Infect Dis 2004; 38:S65-S72.
11. Powderly WG. Antiretroviral therapy in patients with hepatitis and HIV: weighing risks and benefits. Clin Infect Dis 2004; 38:5109-5113.
12. Saves M, Vandentorren S, Daucourt V, et al. Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996-1998. Groupe dEpidemiologie Clinique de Sida en Aquitaine (GECSA). AIDS 1999; 13:F115-F121.
13. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283:74-80.
14. den Brinker M, Wit FW, Wertheim-van Dillen PM, et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000; 14:2895-2902.
15. Saves M, Raffi F, Clevenbergh P, et al. Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. The APROCO Study Group. Antimicrob Agents Chemother 2000; 44:3451-3455.
16. Sulkowski MS, Mehta SH, Chaisson RE, Thomas DL, Moore RD. Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS 2004; 18:2277-2284.
17. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002; 35:182-189.
18. Palmon R, Koo BC, Shoultz DA, Dieterich DT. Lack of hepatotoxicity associated with nonnucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2002; 29:340-345.
19. Lacombe K, Massari V, Girard PM, et al. Major role of hepatitis B genotypes in liver fibrosis during coinfection with HIV. AIDS 2006; 20:419-427.
20. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41:1-19.
21. Wilson JW, Bean P, Robins T, Graziano F, Persing DH. Comparative evaluation of three human immunodeficiency virus genotyping systems: the HIV-GenotypR method, the HIV PRT GeneChip assay, and the HIV-1 RT line probe assay. J Clin Microbiol 2000; 38:3022-3028.
22. Selzer ML, Vinokur A, van Rooijen L. A self-administered Short Michigan Alcoholism Screening Test (SMAST). J Stud Alcohol 1975; 36:117-126.
23. deBénichou C. Criteria of drug-induced liver disorders: report of an international consensus meeting. J Hepatol 1990; 11:272-276
24. AIDS Clinical Trials Group, Table of grading severity of adult adverse experiences. 1996. Rockville, MD: Division of AIDS, National Institute of Allergy and Infectious Diseases.
25. Gentleman RC, Lawless JF, Lindsey JC, Yan P. Multi-state Markov models for analysing incomplete disease history data with illustrations for HIV disease. Stat Med 1994; 13:805-821.
26. Mathieu E, Loup P, Dellamonica P, Daures JP. Markov modelling of immunological and virological states in HIV-1 infected patients. Biom J 2005; 47:834-846.
27. Deuffic-Burban S, Poynard T, Valleron A-J. Quantification of fibrosis progression in patients with chronic hepatitis C using a Markov model. J Viral Hepat 2002; 9:114-122.
28. Corpechot C, Carrat F, Bonnand AM, Poupon RE, Poupon R. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology 2000; 32:1196-1199.
29. Corpechot C, Carrat F, Poupon R, Poupon RE. Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients. Gastroenterology 2002; 122:652-658.
30. Corpechot C, Carrat F, Bahr A, Chretien Y, Poupon RE, Poupon R. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology 2005; 128:297-303.
31. Boudemaghe T, Daures JP. Modéliser l'évolution de l'asthme par des modèles multi-etats [Modeling asthma evolution by a multi-state model]. Rev Epidemiol Sante Publique 2000; 48:249-55. French.
32. Saint-Pierre P, Combescure C, Daures JP, Godard P. The analysis of asthma control under a Markov assumption with use of covariates. Stat Med 2003; 22:3755-3770.
33. Marshall G, Jones RH. Multi-state models and diabetic retinopathy. Stat Med 1995; 14:1975-1983.
34. Rubin DB, Schenker N. Multiple imputation in health-care databases: an overview and some applications. Stat Med 1991; 10:585-598.
35. Stuyver L, De Gendt S, Van Geyt C, et al. A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. J Gen Virol 2000; 81:67-74.
36. Zucker SD, Qin X, Rouster SD, et al. Mechanism of indinavir-induced hyperbilirubinemia. Proc Natl Acad Sci U S A. 2001; 98:12671-12676.
37. Rotger M, Taffe P, Bleiber G, et al. Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. J Infect Dis. 2005; 192:1381-1386.
38. Cicconi P, Cozzi-Lepri A, Phillips A, et al. Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy? AIDS 2007; 21:599-606.
39. Becker S. Liver toxicity in epidemiological cohorts. Clin Infect Dis 2004; 38:S49-S55.
40. Martinez E, Blanco JL, Arnaiz JA, et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 2001; 15:1261-1268.
41. Carr A, Cooper DA. Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor. Lancet 1997; 349:995-996
42. Manegold C, Hannoun C, Wywiol A, Dietrich et al. Reactivation of hepatitis B virus replication accompanied by acute hepatitis in patients receiving highly active antiretroviral therapy. Clin Infect Dis 2001; 32:144-148.
43. Bruno R, Sacchi P, Malfitano A, et al. YMDD-mutant HBV strain as a cause of liver failure in an HIV-infected patient. Gastroenterology 2001; 121:1027-1028.
44. Michalak TI, Lau JY, McFarlane BM, Alexander GJ, Eddleston AL, Williams R. Antibody-directed complement-mediated cytotoxicity to hepatocytes from patients with chronic hepatitis B. Clin Exp Immunol 1995; 100:227-232.
45. Fung SK, Lok AS. Hepatitis B virus genotypes: do they play a role in the outcome of HBV infection? Hepatology 2004; 40:790-792.
46. Mills CT, Lee E, Perrillo R. Relationship between histology, aminotransferase levels, and viral replication in chronic hepatitis B. Gastroenterology 1990; 99:519-524.
47. Poynard T, Mathurin P, Lai CL, et al. A comparison of fibrosis progression in chronic liver diseases. J Hepatol 2003; 38:257-265.
48. Pol S, Wesenfelder L, Dubois F, et al. Influence of human immunodeficiency virus infection on hepatitis delta virus superinfection in chronic HBsAg carriers. J Viral Hepat 1994; 1:131-137.
49. Ganem D, Prince AM. Hepatitis B virus infection - natural history and clinical consequences. N Engl J Med 2004; 350:1118-1129.
50. Riddler SA, Haubrich R, DiRienzo G, et al. A prospective, randomized, phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection: ACTG 5142. XVI International AIDS Conference. 13-18 August 2006, Toronto, Canada. Abstract THLB0204.